A-3 Price List - Sitagliptan-Metformin - Diabetes Non-Insulin - DPP-4 Inh.xlsx

XLSX spreadsheet 48 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation number
HT9402-24-Q-9304
Issued by

About this file

This document is a Request for Quotation (RFQ) for the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement and Uniform Formulary Additional Discount Program. The RFQ is soliciting quotes from industry for newly approved pharmaceutical agents within the Diabetes Non-Insulin, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors drug class, to be reviewed at the August 2024 DoD Pharmacy and Therapeutics (P&T) Committee meeting. The RFQ includes appendices for the Uniform Formulary Blanket Purchase Agreement and Uniform Formulary Additional Discount Program, which detail the formulary scenarios, pricing, and refund requirements. Responses to the RFQ are due by July 18, 2024, and a pre-quotation teleconference will be held on July 10, 2024. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the P&T Committee's decisions.

View the file

Other files

Show all 14

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the August 2024 DoD P&T Meeting
DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes generic agents for all new and current users. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete or partial exclusion from the TRICARE pharmacy benefit program. Metformin or a sulfonylurea must be utilized prior to any agent(s) that reside in this subclass regardless of step therapy status. Families will be considered one brand agent for bidding purposes as long as they are priced accordingly.

Step Therapy Addendum: Grandfathering: a prior authorization process would require new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user. Agents with RFQ not submitted or selected may be designated non-step preferred. Subclass agents compete only against each other and only after metformin or sulfonylurea have been tried.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1121DNDP1UFAS1MUniform Formulary
After Step Therapy1or moreNO QUOTE
121DNDP1NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the August 2024 DoD P&T Meeting
DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes generic agents for all new and current users. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete or partial exclusion from the TRICARE pharmacy benefit program. Metformin or a sulfonylurea must be utilized prior to any agent(s) that reside in this subclass regardless of step therapy status. Families will be considered one brand agent for bidding purposes as long as they are priced accordingly.

Step Therapy Addendum: Grandfathering: a prior authorization process would require new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user. Agents with RFQ not submitted or selected may be designated non-step preferred. Subclass agents compete only against each other and only after metformin or sulfonylurea have been tried.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
0
Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

ADP (WAC Discount)

UF ADP Appendix for the August 2024 DoD P&T Meeting
DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes generic agents for all new and current users. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete or partial exclusion from the TRICARE pharmacy benefit program. Metformin or a sulfonylurea must be utilized prior to any agent(s) that reside in this subclass regardless of step therapy status. Families will be considered one brand agent for bidding purposes as long as they are priced accordingly.

Step Therapy Addendum: Grandfathering: a prior authorization process, would require new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a user. Agents with RFQ not submitted or selected may be designated non-step preferred. Subclass agents compete only against each other and only after metformin or sulfonylurea have been tried.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:DIABETES NON-INSULINP&T Committee Meeting:August 7-8, 2024
DOD Uniform Formulary Subclass:DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORSQuotes due:July 18, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1121DNDP1T2AS1MTier 2
After Step Therapy1 or more
121DNDP1T3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .